FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2778575734> ?p ?o ?g. }

• W2778575734 endingPage "907.e1" @default.
• W2778575734 startingPage "900" @default.
• W2778575734 abstract "Background & AimsEpithelioid granulomas are characteristics of a subset of patients with Crohn’s disease (CD), but their significance, with regard to disease progression and severity, is unclear. We investigated the relationship between granulomas and CD severity over a 6-year time period in a large cohort of patients.MethodsWe performed a retrospective study of patients with CD seen at the Inflammatory Bowel Disease Center at the University of Pittsburgh; data were collected from 2009 through 2014 and patients were assigned to groups with and without histologic evidence of granuloma. Demographic, clinical (including disease activity, quality of life, medication use, and healthcare utilization), and laboratory data were used in association and survival analyses. Differences between groups were evaluated using the Mann-Whitney U-test for continuous variables.ResultsOf 1466 patients with CD, granulomas were identified in 187 (12.8%). In the subset of patients who underwent surgery, 21.0% had granulomas. The presence of granuloma was associated with increased serum levels of c-reactive protein (odds ratio [OR], 2.9; 95% CI, 2.078–4.208; P < .0001), younger mean age at diagnosis (23.6 ± 11.3 years in patients with granulomas vs 27.9 ± 13.3 years in patients without; P = .0005), higher rates of stricturing or penetrating disease phenotype, higher rates of steroid and narcotic use, and higher healthcare utilization. Among patients that underwent surgery, the presence of granulomas was associated with need for repeat surgery during the 6-year observation period (OR, 2.5; 95% CI, 1.54–4.02; P = .0002). Infliximab use was associated with detection of granuloma in a significantly lower proportion of surgical specimens compared to patients who had not been treated with a biologic agent (OR, 0.22; 95 CI, 0.05–0.97; P = .03).ConclusionsEpithelioid granulomas develop in less than 13% of patients with CD, and are associated with a more aggressive disease phenotype. Patients who have undergone surgery for CD and have granulomas are at increased risk for repeat surgery within 6 years. Epithelioid granulomas are characteristics of a subset of patients with Crohn’s disease (CD), but their significance, with regard to disease progression and severity, is unclear. We investigated the relationship between granulomas and CD severity over a 6-year time period in a large cohort of patients. We performed a retrospective study of patients with CD seen at the Inflammatory Bowel Disease Center at the University of Pittsburgh; data were collected from 2009 through 2014 and patients were assigned to groups with and without histologic evidence of granuloma. Demographic, clinical (including disease activity, quality of life, medication use, and healthcare utilization), and laboratory data were used in association and survival analyses. Differences between groups were evaluated using the Mann-Whitney U-test for continuous variables. Of 1466 patients with CD, granulomas were identified in 187 (12.8%). In the subset of patients who underwent surgery, 21.0% had granulomas. The presence of granuloma was associated with increased serum levels of c-reactive protein (odds ratio [OR], 2.9; 95% CI, 2.078–4.208; P < .0001), younger mean age at diagnosis (23.6 ± 11.3 years in patients with granulomas vs 27.9 ± 13.3 years in patients without; P = .0005), higher rates of stricturing or penetrating disease phenotype, higher rates of steroid and narcotic use, and higher healthcare utilization. Among patients that underwent surgery, the presence of granulomas was associated with need for repeat surgery during the 6-year observation period (OR, 2.5; 95% CI, 1.54–4.02; P = .0002). Infliximab use was associated with detection of granuloma in a significantly lower proportion of surgical specimens compared to patients who had not been treated with a biologic agent (OR, 0.22; 95 CI, 0.05–0.97; P = .03). Epithelioid granulomas develop in less than 13% of patients with CD, and are associated with a more aggressive disease phenotype. Patients who have undergone surgery for CD and have granulomas are at increased risk for repeat surgery within 6 years." @default.
• W2778575734 created "2018-01-05" @default.
• W2778575734 creator A5002303350 @default.
• W2778575734 creator A5003700750 @default.
• W2778575734 creator A5007679045 @default.
• W2778575734 creator A5008772870 @default.
• W2778575734 creator A5012841875 @default.
• W2778575734 creator A5015029502 @default.
• W2778575734 creator A5021999810 @default.
• W2778575734 creator A5022105097 @default.
• W2778575734 creator A5029702679 @default.
• W2778575734 creator A5036719219 @default.
• W2778575734 creator A5070623708 @default.
• W2778575734 creator A5078832003 @default.
• W2778575734 creator A5081982229 @default.
• W2778575734 creator A5085664543 @default.
• W2778575734 date "2018-06-01" @default.
• W2778575734 modified "2023-10-15" @default.
• W2778575734 title "Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn’s Disease, Based on 6-Year Follow-Up" @default.
• W2778575734 cites W1026683324 @default.
• W2778575734 cites W1468685218 @default.
• W2778575734 cites W1579585566 @default.
• W2778575734 cites W1942412715 @default.
• W2778575734 cites W1978368874 @default.
• W2778575734 cites W1994095663 @default.
• W2778575734 cites W1994536516 @default.
• W2778575734 cites W2001492734 @default.
• W2778575734 cites W2028040906 @default.
• W2778575734 cites W2033884307 @default.
• W2778575734 cites W2059904611 @default.
• W2778575734 cites W2073426442 @default.
• W2778575734 cites W2083523349 @default.
• W2778575734 cites W2092201943 @default.
• W2778575734 cites W2094235275 @default.
• W2778575734 cites W2098411479 @default.
• W2778575734 cites W2111282166 @default.
• W2778575734 cites W2111365542 @default.
• W2778575734 cites W2117207917 @default.
• W2778575734 cites W2156733583 @default.
• W2778575734 cites W2188248802 @default.
• W2778575734 cites W2313977479 @default.
• W2778575734 cites W2317191331 @default.
• W2778575734 cites W2333248612 @default.
• W2778575734 cites W24555878 @default.
• W2778575734 cites W2519030814 @default.
• W2778575734 cites W4250543871 @default.
• W2778575734 doi "https://doi.org/10.1016/j.cgh.2017.12.034" @default.
• W2778575734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29277619" @default.
• W2778575734 hasPublicationYear "2018" @default.
• W2778575734 type Work @default.
• W2778575734 sameAs 2778575734 @default.
• W2778575734 citedByCount "23" @default.
• W2778575734 countsByYear W27785757342019 @default.
• W2778575734 countsByYear W27785757342020 @default.
• W2778575734 countsByYear W27785757342021 @default.
• W2778575734 countsByYear W27785757342022 @default.
• W2778575734 countsByYear W27785757342023 @default.
• W2778575734 crossrefType "journal-article" @default.
• W2778575734 hasAuthorship W2778575734A5002303350 @default.
• W2778575734 hasAuthorship W2778575734A5003700750 @default.
• W2778575734 hasAuthorship W2778575734A5007679045 @default.
• W2778575734 hasAuthorship W2778575734A5008772870 @default.
• W2778575734 hasAuthorship W2778575734A5012841875 @default.
• W2778575734 hasAuthorship W2778575734A5015029502 @default.
• W2778575734 hasAuthorship W2778575734A5021999810 @default.
• W2778575734 hasAuthorship W2778575734A5022105097 @default.
• W2778575734 hasAuthorship W2778575734A5029702679 @default.
• W2778575734 hasAuthorship W2778575734A5036719219 @default.
• W2778575734 hasAuthorship W2778575734A5070623708 @default.
• W2778575734 hasAuthorship W2778575734A5078832003 @default.
• W2778575734 hasAuthorship W2778575734A5081982229 @default.
• W2778575734 hasAuthorship W2778575734A5085664543 @default.
• W2778575734 hasBestOaLocation W27785757341 @default.
• W2778575734 hasConcept C126322002 @default.
• W2778575734 hasConcept C141071460 @default.
• W2778575734 hasConcept C142724271 @default.
• W2778575734 hasConcept C156957248 @default.
• W2778575734 hasConcept C167135981 @default.
• W2778575734 hasConcept C2777138892 @default.
• W2778575734 hasConcept C2778260677 @default.
• W2778575734 hasConcept C2779134260 @default.
• W2778575734 hasConcept C2779280984 @default.
• W2778575734 hasConcept C2780140890 @default.
• W2778575734 hasConcept C71924100 @default.
• W2778575734 hasConcept C72563966 @default.
• W2778575734 hasConcept C90924648 @default.
• W2778575734 hasConceptScore W2778575734C126322002 @default.
• W2778575734 hasConceptScore W2778575734C141071460 @default.
• W2778575734 hasConceptScore W2778575734C142724271 @default.
• W2778575734 hasConceptScore W2778575734C156957248 @default.
• W2778575734 hasConceptScore W2778575734C167135981 @default.
• W2778575734 hasConceptScore W2778575734C2777138892 @default.
• W2778575734 hasConceptScore W2778575734C2778260677 @default.
• W2778575734 hasConceptScore W2778575734C2779134260 @default.
• W2778575734 hasConceptScore W2778575734C2779280984 @default.
• W2778575734 hasConceptScore W2778575734C2780140890 @default.
• W2778575734 hasConceptScore W2778575734C71924100 @default.
• W2778575734 hasConceptScore W2778575734C72563966 @default.

• next